Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023
08 juin 2023 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present nine abstracts, including the interim...
Travere Therapeutics to Present at Upcoming Investor Conferences
01 juin 2023 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, June 01, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming conferences: William...
Travere Therapeutics Announces Positive Topline Results from Cohort 6 in the Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria
31 mai 2023 07h00 HE
|
Travere Therapeutics, Inc.
Data from the four patients treated with the highest dose of pegtibatinase showed a clinically meaningful 67.1% mean relative reduction in total homocysteine from baseline Pegtibatinase has...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 mai 2023 17h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May 10, 2023, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics Reports First Quarter 2023 Financial Results
04 mai 2023 16h01 HE
|
Travere Therapeutics, Inc.
FILSPARI™(sparsentan) granted accelerated approval by FDA for the reduction of proteinuria in IgA nephropathy (IgAN) on February 17th, 2023; commercial launch underway Total net product sales of...
Travere Therapeutics Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
01 mai 2023 16h05 HE
|
Travere Therapeutics, Inc.
The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended favorably for sparsentan Treatment with...
Travere Therapeutics to Report First Quarter 2023 Financial Results
26 avr. 2023 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, April 26, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2023 financial results on Thursday, May 4, 2023, after the close...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 avr. 2023 17h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, April 13, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on April 10, 2023, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023
01 avr. 2023 04h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, April 01, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced publication in The Lancet of the interim analysis of efficacy and safety data from the ongoing...
Travere Therapeutics to Present at Upcoming Investor Conferences
28 mars 2023 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, March 28, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming conferences: Guggenheim...